Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.
Standard
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. / Haro, Josep Maria; Suarez, David; Novick, Diego; Brown, Jacqueline; Usall, Judith; Naber, Dieter.
In: EUR NEUROPSYCHOPHARM, Vol. 17, No. 4, 4, 2007, p. 235-244.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.
AU - Haro, Josep Maria
AU - Suarez, David
AU - Novick, Diego
AU - Brown, Jacqueline
AU - Usall, Judith
AU - Naber, Dieter
PY - 2007
Y1 - 2007
N2 - Antipsychotic discontinuation rates are a powerful indicator of medication effectiveness in schizophrenia. We examined antipsychotic discontinuation in the Schizophrenia Outpatient Health Outcomes (SOHO) study, a 3-year prospective, observational study in outpatients with schizophrenia in 10 European countries. Patients (n=7728) who started antipsychotic monotherapy were analyzed. Medication discontinuation for any cause ranged from 34% and 36% for clozapine and olanzapine, respectively, to 66% for quetiapine. Compared to olanzapine, the risk of treatment discontinuation before 36 months was significantly higher for quetiapine, risperidone, amisulpride, and typical antipsychotics (oral and depot), but similar for clozapine. Longer medication maintenance was associated with being socially active and having a longer time since first treatment contact for schizophrenia, whereas higher symptom severity, treatment with mood stabilizers, substance abuse, having hostile behaviour were associated with lower medication maintenance. Antipsychotic maintenance in SOHO was higher than the results of previous randomized studies.
AB - Antipsychotic discontinuation rates are a powerful indicator of medication effectiveness in schizophrenia. We examined antipsychotic discontinuation in the Schizophrenia Outpatient Health Outcomes (SOHO) study, a 3-year prospective, observational study in outpatients with schizophrenia in 10 European countries. Patients (n=7728) who started antipsychotic monotherapy were analyzed. Medication discontinuation for any cause ranged from 34% and 36% for clozapine and olanzapine, respectively, to 66% for quetiapine. Compared to olanzapine, the risk of treatment discontinuation before 36 months was significantly higher for quetiapine, risperidone, amisulpride, and typical antipsychotics (oral and depot), but similar for clozapine. Longer medication maintenance was associated with being socially active and having a longer time since first treatment contact for schizophrenia, whereas higher symptom severity, treatment with mood stabilizers, substance abuse, having hostile behaviour were associated with lower medication maintenance. Antipsychotic maintenance in SOHO was higher than the results of previous randomized studies.
M3 - SCORING: Zeitschriftenaufsatz
VL - 17
SP - 235
EP - 244
JO - EUR NEUROPSYCHOPHARM
JF - EUR NEUROPSYCHOPHARM
SN - 0924-977X
IS - 4
M1 - 4
ER -
